Paclitaxel nonsmall-cell lung cancer

Lau et al. have reported on their experience of administering radiation with taxol dosed twice a week for locally advanced nonsmall-cell lung cancer (53). Their phase II trial was conducted combining low-dose radiosensitizing chemotherapy with concurrent radiation followed by consolidation chemotherapy (62). The induction chemoradiation consisted of paclitaxel, 30 mg/m2 iv over 1 h, twice weekly for 6 wk carboplatin, AUC of... 

Paclitaxel Taxol Carcinoma of the breast, ovaries Kaposi sarcoma nonsmall cell lung cancer Blood disorders (anemia, leukopenia, neutropenia, thrombocytopenia] hypersensitivity reaction (skin rash/itching, shortness of breath] joint/muscle pain peripheral neuropathies Gl distress (nausea, vomiting, diarrhea]... 

In vitro studies with several tumor cell lines have shown vitamin C to enhance the cytotoxic activity of doxorubicin, cisplatin, paclitaxel, dacarbazine, 5-FU, and bleomycin. Vitamin C has also been shown to increase drug accumulation and to partially reverse vincristine resistance of human nonsmall-cell lung cancer cells. 

Kelly K, Mikhaeel-Kamel N, Pan Z, et al. A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced nonsmall cell lung cancer. Clin Cancer Res 2000 6 3474-3479. 

CP carboplatin-paclitaxel 5-FU 5-fluorouracil HNSCC head and neck squamous cell carcinoma IFL irinotecan, 5-fluorouraciI, leucovorin N number of patients NR not reported CRC colorectal cancer NSCLC nonsmall cell lung cancer OS overall survival PFS progression-free survival RR response rate RT radiotherapy. 

Shord SS, Faucette SR, Gillenwater HH, Pescatore SL, Hawke RL, Socinski MA, Lindley C. Gemeitabine pharmacokinetics and interaction with paclitaxel in patients with advanced nonsmall-cell lung cancer. Cancer Chemother Pharmacol lOOT) 51,328-36. 

Socinski M A, Rosenman JG, Schell MJ, et al. Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall-cell lung carcinoma a modified Phase I trial. Cancer 2000 89(3) 534-542. 

---